Literature DB >> 19520461

[Prevalence of irritable bowel syndrome and associated factors according to the Rome III diagnostic criteria in a general population in Colombia].

David Felipe Gómez Alvarez1, Julián Guillermo Morales Vargas, Luís Mariano Aurelio Rojas Medina, Sandra Celina Mújica Oviedo, Paul Anthony Camacho López, Germán Eduardo Rueda Jaimes.   

Abstract

INTRODUCTION: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder with a clinical diagnosis. The prevalence of this disorder and associated factors are unknown among the Colombian population. Nowadays, diagnosis of IBS is made by applying the Rome III criteria, and other disorders should be excluded before establishing the diagnosis.
OBJECTIVE: To assess the prevalence of IBS and associated factors in a population aged between 18 and 60 years old in Bucaramanga, Colombia.
METHODS: A cross-sectional study was performed. We applied a questionnaire that included sociodemographic variables, types of food, identification of IBS by the Rome III criteria, the Zung self-rating depression scale, the State-Trait Anxiety Inventory (STAI) test and self-reported use of medical services among a random sample of an adult population in Bucaramanga. Univariate analysis and logistic regression was used to establish associations.
RESULTS: Of the 615 individuals selected, 558 were included in the study. The mean age was 36.4 years and 62.4% was female. The prevalence of IBS was 19.9%. Logistic regression analysis showed an association with depressive symptoms and female sex independently of age and anxiety symptoms.
CONCLUSIONS: The prevalence of IBS is high and is associated with depressive symptoms and female sex in an adult population in Colombia. This disorder generates substantial health system utilization and medical disability and restricts activities of daily life.

Entities:  

Mesh:

Year:  2009        PMID: 19520461     DOI: 10.1016/j.gastrohep.2009.01.177

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  8 in total

1.  Prevalence and risk factors of irritable bowel syndrome in healthy screenee undergoing colonoscopy and laboratory tests.

Authors:  Su Youn Nam; Byung Chang Kim; Kum Hei Ryu; Bum Joon Park
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

Review 2.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

3.  Prevalence and risk factors of irritable bowel syndrome in Asia.

Authors:  Oh Young Lee
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

4.  The current prevalence of irritable bowel syndrome in Asia.

Authors:  Full-Young Chang; Ching-Liang Lu; Tseng-Shing Chen
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

5.  The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study.

Authors:  Aurelio López-Colombo; Douglas Morgan; Dalia Bravo-González; Alvaro Montiel-Jarquín; Socorro Méndez-Martínez; Max Schmulson
Journal:  Gastroenterol Res Pract       Date:  2012-03-19       Impact factor: 2.260

6.  Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World.

Authors:  Tadayuki Oshima; Hiroto Miwa
Journal:  J Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 4.924

7.  Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian University: an electronic survey.

Authors:  Martín Cañón; Alvaro J Ruiz; Martín Rondón; Jaime Alvarado
Journal:  Ann Gastroenterol       Date:  2016-09-30

8.  Irritable bowel syndrome is associated with gastroesophageal reflux symptom but not erosive esophagitis.

Authors:  Su Youn Nam; Kum Hei Ryu; Bum Joon Park
Journal:  J Neurogastroenterol Motil       Date:  2013-10-07       Impact factor: 4.924

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.